TRON · Tron Inc.

The reported securities are held directly by Bravemorning Limited ("Bravemorning"). Mr. Weike Sun is the sole shareholder of Bravemorning and may be deemed to beneficially own the securities held by Bravemorning. On June 16, 2025, Bravemorning purchased (i) 100,000 shares of Series B Convertible Preferred Stock, convertible into 200,000,000 shares of the Registrant's common stock at a conversion price of $0.50 per share and (ii) warrants to purchase up to 220,000,000 shares of the Registrant's common stock at an exercise price of $0.50 per share (the "PIPE Warrants") with the consideration of $100,000,000 paid in the form of 365,096,845 TRX.

On April 2, 2026, the Registrant received a conversion notice from Bravemorning to convert all of its 100,000 shares of Series B Preferred Stock and, on April 2, 2026, the Registrant issued 200,000,000 shares of Common Stock to Bravemorning.

These securities do not have an expiration date.

The reported securities are held directly by Bravemorning Limited ("Bravemorning"). Mr. Weike Sun is the sole shareholder of Bravemorning and may be deemed to beneficially own the securities held by Bravemorning. On June 16, 2025, Bravemorning purchased (i) 100,000 shares of Series B Convertible Preferred Stock, convertible into 200,000,000 shares of the Registrant's common stock at a conversion price of $0.50 per share and (ii) warrants to purchase up to 220,000,000 shares of the Registrant's common stock at an exercise price of $0.50 per share (the "PIPE Warrants") with the consideration of $100,000,000 paid in the form of 365,096,845 TRX.

On August 27, 2025, Bravemorning exercised the PIPE Warrants in full and, on August 29, 2025, the Registrant issued 220,000,000 shares of Common Stock to Bravemorning. The Holder paid $110,000,000 to the Registrant in the form of 312,500,100 TRX as consideration for the issuance of these Common Stock shares.

The reported securities are held directly by Bravemorning Limited ("Bravemorning"). Mr. Weike Sun is the sole shareholder of Bravemorning and may be deemed to beneficially own the securities held by Bravemorning. On June 16, 2025, Bravemorning purchased (i) 100,000 shares of Series B Convertible Preferred Stock, convertible into 200,000,000 shares of the Registrant's common stock at a conversion price of $0.50 per share and (ii) warrants to purchase up to 220,000,000 shares of the Registrant's common stock at an exercise price of $0.50 per share (the "PIPE Warrants") with the consideration of $100,000,000 paid in the form of 365,096,845 TRX.

The reported securities are held directly by Bravemorning Limited ("Bravemorning"). Mr. Weike Sun is the sole shareholder of Bravemorning and may be deemed to beneficially own the securities held by Bravemorning. On June 16, 2025, Bravemorning purchased (i) 100,000 shares of Series B Convertible Preferred Stock, convertible into 200,000,000 shares of the Registrant's common stock at a conversion price of $0.50 per share and (ii) warrants to purchase up to 220,000,000 shares of the Registrant's common stock at an exercise price of $0.50 per share (the "PIPE Warrants") with the consideration of $100,000,000 paid in the form of 365,096,845 TRX.

The 135,000 stock options were issued pursuant to the Company's 2024 Equity Incentive Plan.

The stock options ("Options") were issued pursuant to the Company's 2024 Equity Incentive Plan.

The 65,000 stock options were issued pursuant to the Company's 2023 Equity Incentive Plan.

The stock options ("Options") were issued pursuant to the Company's 2024 Equity Incentive Plan. The 50,000 Options were exercised cashlessly resulting in the issuance of 46,818 shares of common stock.

The shares of common stock sold were acquired through the exercise of stock options, which were granted pursuant to the Company's 2024 Equity Incentive Plan.

The shares of common stock sold were acquired through the exercise of stock options, which were granted pursuant to the Company's 2024 Equity Incentive Plan.

The shares of common stock sold were acquired through the exercise of stock options, which were granted pursuant to the Company's 2024 Equity Incentive Plan.

The shares of common stock sold were acquired through the exercise of stock options, which were granted pursuant to the Company's 2024 Equity Incentive Plan.

The shares of common stock sold were acquired through the exercise of stock options, which were granted pursuant to the Company's 2024 Equity Incentive Plan.

The stock options were issued pursuant to the Company's 2023 Equity Incentive Plan.

The stock options ("Options") were issued pursuant to the Company's 2024 Equity Incentive Plan.

The stock options were issued pursuant to the Company's 2023 Equity Incentive Plan.

The shares of common stock sold were acquired through the previously disclosed June 17, 2025 exercise of stock options, which were granted pursuant to the Company's 2023 Equity Incentive Plan.

The shares of common stock sold were acquired through the previously disclosed June 17, 2025 exercise of stock options, which were granted pursuant to the Company's 2023 Equity Incentive Plan.

The shares of common stock sold were acquired through the previously disclosed June 17, 2025 exercise of stock options, which were granted pursuant to the Company's 2023 Equity Incentive Plan.

The shares of common stock sold were acquired through the previously disclosed June 17, 2025 exercise of stock options, which were granted pursuant to the Company's 2023 Equity Incentive Plan.

The shares of common stock sold were acquired through the previously disclosed June 17, 2025 exercise of stock options, which were granted pursuant to the Company's 2023 Equity Incentive Plan.

The shares of common stock sold were acquired through the previously disclosed June 17, 2025 exercise of stock options, which were granted pursuant to the Company's 2023 Equity Incentive Plan.

The shares of common stock sold were acquired through the previously disclosed June 17, 2025 exercise of stock options, which were granted pursuant to the Company's 2023 Equity Incentive Plan.

The shares of common stock sold were acquired through the previously disclosed June 17, 2025 exercise of stock options, which were granted pursuant to the Company's 2023 Equity Incentive Plan.

The shares of common stock sold were acquired through the previously disclosed June 17, 2025 exercise of stock options, which were granted pursuant to the Company's 2023 Equity Incentive Plan.

The shares of common stock sold were acquired through the previously disclosed June 17, 2025 exercise of stock options, which were granted pursuant to the Company's 2023 Equity Incentive Plan.

The shares of common stock sold were acquired through the previously disclosed June 17, 2025 exercise of stock options, which were granted pursuant to the Company's 2023 Equity Incentive Plan.

The shares of common stock sold were acquired through the previously disclosed June 17, 2025 exercise of stock options, which were granted pursuant to the Company's 2023 Equity Incentive Plan.

The shares of common stock sold were acquired through the previously disclosed June 17, 2025 exercise of stock options, which were granted pursuant to the Company's 2023 Equity Incentive Plan.

The shares of common stock sold were acquired through the previously disclosed June 17, 2025 exercise of stock options, which were granted pursuant to the Company's 2023 Equity Incentive Plan.

The shares of common stock sold were acquired through the previously disclosed June 17, 2025 exercise of stock options, which were granted pursuant to the Company's 2023 Equity Incentive Plan.

The shares of common stock sold were acquired through the previously disclosed June 17, 2025 exercise of stock options, which were granted pursuant to the Company's 2023 Equity Incentive Plan.

The shares of common stock sold were acquired through the previously disclosed June 17, 2025 exercise of stock options, which were granted pursuant to the Company's 2023 Equity Incentive Plan.

The shares of common stock sold were acquired through the previously disclosed June 17, 2025 exercise of stock options, which were granted pursuant to the Company's 2023 Equity Incentive Plan.

The shares of common stock sold were acquired through the previously disclosed June 17, 2025 exercise of stock options, which were granted pursuant to the Company's 2023 Equity Incentive Plan.

The stock options were issued pursuant to the Company's 2023 Equity Incentive Plan.

The stock options ("Options") were issued pursuant to the Company's 2024 Equity Incentive Plan.

The stock options ("Options") were issued pursuant to the Company's 2024 Equity Incentive Plan. The issuance was approved by the members of the Compensation Committee of the Board of Directors prior to the close of trading on the Nasdaq Capital Market on May 23, 2025. The Options will vest and become exercisable immediately and shall expire on May 23, 2030.

The stock options ("Options") were issued pursuant to the Company's 2024 Equity Incentive Plan. The issuance was approved by the members of the Compensation Committee of the Board of Directors prior to the close of trading on the Nasdaq Capital Market on May 23, 2025. The Options will vest and become exercisable immediately and shall expire on May 23, 2030.

The Options were issued pursuant to the Company's 2024 Equity Incentive Plan. The issuance was approved by the members of the Compensation Committee of the Board of Directors prior to the close of trading on the Nasdaq Capital Market on May 23, 2025. The Options will vest and become exercisable immediately and shall expire on May 23, 2030.